Shingles Vaccine Market Size, Share, Trends, Growth Outlook

Shingles Vaccine Market is estimated to increase at a growth rate of 9.4% CAGR over the forecast period from 2024 to 2030.

The global Shingles Vaccine Marketstudy analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Product (Shingrix, Zostavax, SKYZoster), By Type (Recombinant Vaccine, Live Attenuated Vaccine).

An introduction to Shingles Vaccine Market in 2024

Addressing the prevention of herpes zoster, commonly known as shingles, the Shingles Vaccine Market offers vaccines designed to reduce the risk and severity of this painful and debilitating viral infection. Shingles are caused by the reactivation of the varicella-zoster virus, which also causes chickenpox, primarily affecting older adults and individuals with weakened immune systems. Vaccination is the most effective strategy for preventing shingles and its complications, including postherpetic neuralgia. This market encompasses live attenuated and recombinant vaccines administered to individuals aged 50 and older, provided by pharmaceutical companies, healthcare providers, and public health agencies. With an aging population and increasing awareness of the importance of adult vaccination, the demand for shingles vaccines continues to grow, driven by efforts to reduce the disease burden and improve the quality of life for older adults. As healthcare systems prioritize preventive care and immunization initiatives, the Shingles Vaccine Market remains vital in protecting vulnerable populations from vaccine-preventable diseases.

Shingles Vaccine Market Trend: Increasing Focus on Prevention and Immunization

A prominent trend in the Shingles Vaccine market is the increasing focus on prevention and immunization against herpes zoster virus. With aging populations and the associated higher risk of developing shingles, there's a growing awareness among healthcare providers and patients about the importance of vaccination as a preventive measure. Efforts to promote adult immunization programs, public health campaigns, and recommendations from healthcare organizations contribute to greater uptake of shingles vaccines. Additionally, advancements in vaccine formulations and delivery methods, such as the availability of adjuvanted and recombinant vaccines, cater to diverse patient populations and enhance vaccine efficacy, driving growth in the shingles vaccine market as prevention becomes a priority in healthcare strategies.

Shingles Vaccine Market Driver: Aging Population and Increased Disease Burden

A key driver propelling the growth of the Shingles Vaccine market is the aging population demographic and the associated increased disease burden of herpes zoster. As the global population continues to age, the prevalence of shingles and its complications, including postherpetic neuralgia (PHN), rises significantly. The impact of shingles on quality of life, healthcare utilization, and economic costs underscores the importance of vaccination in reducing disease incidence, severity, and associated complications among older adults. Healthcare providers, policymakers, and payers recognize the value of shingles vaccination as a cost-effective strategy for preventing shingles-related morbidity and reducing healthcare expenditures, driving demand for shingles vaccines and supporting market growth.

Shingles Vaccine Market Opportunity: Expansion into Emerging Markets and High-Risk Populations

An opportunity in the Shingles Vaccine market lies in the expansion into emerging markets and high-risk populations that are currently underserved or have low vaccine coverage rates. While vaccination against shingles is more established in developed countries with aging populations, there's untapped potential in emerging markets where awareness, access to vaccines, and healthcare infrastructure may be limited. Targeting high-risk populations, such as immunocompromised individuals, transplant recipients, and those with chronic medical conditions, presents an opportunity to address unmet medical needs and expand the market for shingles vaccines. Collaborations with local healthcare authorities, advocacy groups, and international organizations can facilitate vaccine access, distribution, and education efforts, unlocking new growth opportunities in previously untapped segments of the shingles vaccine market.

Shingles Vaccine Market Market Segmentation

By Product
Shingrix
Zostavax
SKYZoster
By Type
Recombinant Vaccine
Live Attenuated Vaccine

Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Shingles Vaccine Market Companies

CanSinoBIO
Changchun BCHT Biotechnology Co
Curevo Inc
Geneone Life Science
GSK plc
Jiangsu Recbio Technology Co. Ltd
Merck & Co. Inc
Pfizer Inc
SK chemicals
Vaccitech

Reasons to Buy the Shingles Vaccine Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Shingles Vaccine Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Shingles Vaccine Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Shingles Vaccine Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Shingles Vaccine Market Size Outlook, $ Million, 2021 to 2030
3.2 Shingles Vaccine Market Outlook by Type, $ Million, 2021 to 2030
3.3 Shingles Vaccine Market Outlook by Product, $ Million, 2021 to 2030
3.4 Shingles Vaccine Market Outlook by Application, $ Million, 2021 to 2030
3.5 Shingles Vaccine Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Shingles Vaccine Industry
4.2 Key Market Trends in Shingles Vaccine Industry
4.3 Potential Opportunities in Shingles Vaccine Industry
4.4 Key Challenges in Shingles Vaccine Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Shingles Vaccine Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Shingles Vaccine Market Outlook by Segments
7.1 Shingles Vaccine Market Outlook by Segments, $ Million, 2021- 2030
By Product
Shingrix
Zostavax
SKYZoster
By Type
Recombinant Vaccine
Live Attenuated Vaccine

8 North America Shingles Vaccine Market Analysis and Outlook To 2030
8.1 Introduction to North America Shingles Vaccine Markets in 2024
8.2 North America Shingles Vaccine Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Shingles Vaccine Market size Outlook by Segments, 2021-2030
By Product
Shingrix
Zostavax
SKYZoster
By Type
Recombinant Vaccine
Live Attenuated Vaccine

9 Europe Shingles Vaccine Market Analysis and Outlook To 2030
9.1 Introduction to Europe Shingles Vaccine Markets in 2024
9.2 Europe Shingles Vaccine Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Shingles Vaccine Market Size Outlook by Segments, 2021-2030
By Product
Shingrix
Zostavax
SKYZoster
By Type
Recombinant Vaccine
Live Attenuated Vaccine

10 Asia Pacific Shingles Vaccine Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Shingles Vaccine Markets in 2024
10.2 Asia Pacific Shingles Vaccine Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Shingles Vaccine Market size Outlook by Segments, 2021-2030
By Product
Shingrix
Zostavax
SKYZoster
By Type
Recombinant Vaccine
Live Attenuated Vaccine

11 South America Shingles Vaccine Market Analysis and Outlook To 2030
11.1 Introduction to South America Shingles Vaccine Markets in 2024
11.2 South America Shingles Vaccine Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Shingles Vaccine Market size Outlook by Segments, 2021-2030
By Product
Shingrix
Zostavax
SKYZoster
By Type
Recombinant Vaccine
Live Attenuated Vaccine

12 Middle East and Africa Shingles Vaccine Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Shingles Vaccine Markets in 2024
12.2 Middle East and Africa Shingles Vaccine Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Shingles Vaccine Market size Outlook by Segments, 2021-2030
By Product
Shingrix
Zostavax
SKYZoster
By Type
Recombinant Vaccine
Live Attenuated Vaccine

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
CanSinoBIO
Changchun BCHT Biotechnology Co
Curevo Inc
Geneone Life Science
GSK plc
Jiangsu Recbio Technology Co. Ltd
Merck & Co. Inc
Pfizer Inc
SK chemicals
Vaccitech
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Product
Shingrix
Zostavax
SKYZoster
By Type
Recombinant Vaccine
Live Attenuated Vaccine